Here we show that pemetrexed-treated mesothelioma cells undergo accelerated senescence. This is characterized by the secretion of proinflammatory and mitogenic cytokines, reminiscent of an SASP (senescence-associated secretory phenotype). Conditioned media from senescent MPM (malignant pleural mesothelioma) cells trigger the emergence of EMT (epithelial-to-mesenchymal)-like, clonogenic and chemoresistant cell subpopulations, expressing high levels of ALDH (aldehyde dehydrogenase) activity (ALDH bright cells). We show by fluorescence-activated cell sorting of purified ALDH bright and ALDH low cells, that both cell-autonomous and cell-non-autonomous mechanisms converge to maintain the SASP-induced, EMT-like cell subpopulations. Chemoresistant ALDH bright cells exist within primary MPM specimens and enrichment for ALDH bright cells correlates with an earlier tumor onset into NOD/SCID mice. We show that RAS v12 expression induces SASP-like changes in untransformed human mesothelial cells, and that p53 ablation increases the effect of RAS v12 expression. We identify STAT3 activation as a crucial event downstream to SASP signaling. In fact, small hairpin RNA-mediated ablation of STAT3 deeply attenuates the induction of EMT genes and the increase of ALDH bright cells induced by SASP-cytokines. This strongly affects the chemoresistance of MPM cells in vitro and leads to anticancer effects in vivo.
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Introduction
In addition to its role in tumor suppression, cellular senescence is increasingly recognized as an active program of cell stress response characterized by distinct epigenetic and metabolic changes and by broad effector mechanisms, such as DNA damage response (Campisi, 2001; Ben-Porath and Weinberg, 2004) . In addition, genotoxic stress and oncogene expression promote a complex senescence leading to the secretion of cytokines and pro-mitogenic factors, named SASP (senescenceassociated secretory phenotype; Rodier et al., 2005; Young and Narita, 2009; Coppe et al., 2010; Laberge et al., 2011) . SASP-induced chemokines are known to induce EMT (epithelial-to-mesenchymal)-like changes in neighboring cell populations, and this may be considered as a mechanism of tumor progression (Laberge et al., 2011) . However, it is not entirely clear whether SASP signaling can impinge on the progression of the neoplastic disease by modulating chemoresistance and tumor-initiating-activity. Here we aim to investigate this by using malignant pleural mesothelioma (MPM) as an experimental model. MPM can be an appropriate model for this study for several reasons. First, MPM is characterized by an extraordinary resistance to commonly used chemotherapeutic agents, such as pemetrexed and cisplatin, whose administration increases survival of patients of only few months (Hazarika et al., 2005) . Indeed, a large fraction of short-term primary cultures from mesothelioma patients exhibits intermediate-to-extreme drug resistance in vitro (Mujoomdar et al., 2010) . Second, recent evidence show that upregulation of senescence markers in MPM patients undergone platinum-based therapy is associated with a worse prognosis (Sidi et al., 2011) . Third, SASP-induced cytokines are known to be autocrine and paracrine growth-and invasion-promoting signaling molecules for malignant mesothelioma in vitro and in vivo (Fujino et al., 1996; Galffy et al., 1999; Albonici et al., 2009; Hillegass et al., 2010) . In the present work, we show that both pemetrexed treatment and RAS v12 expression trigger SASP-like changes in transformed and untransformed mesothelial cells. This stimulates the emergence of chemoresistant cell subpopulations with features of mesenchymal, tumor-initiating cells. We show that both cell-autonomous and cell-non-autonomous mechanisms maintain the SASP-induced EMT-like cell subpopula-tions. Chemoresistant ALDH (aldehyde dehydrogenase) bright cells exist within primary MPM specimens, and enrichment for ALDH bright cells correlates with an earlier tumor onset in NOD/SCID mice. Finally, we identify STAT3 activation as a crucial event downstream to SASP signaling. shRNA-mediated STAT3 ablation affects the number of ALDH bright cells and the chemoresistance of MPM cells in vitro and in vivo.
Results

MPM cell lines contain clonogenic chemoresistant cell subpopulations
We evaluated the viability of multiple MPM cell lines (and of a primary, untransformed human mesothelial cell line, (HMC) treated with pemetrexed (0-80 mM, 72 h). We observed a dramatic drop in cell viability of HMC cells, while a significant fraction of MPM cells survived the treatment even at high doses of pemetrexed ( Figure 1a ). Drug-response assay performed with surviving (replated) MPM cells confirmed a relative increase of chemoresistant cells, as shown by increased CC 50 (cytotoxic concentration, the concentration that reduces cell viability by 50%) values (Supplementary Figures 1A and B ). Clonogenic assays with either shortterm-treated (5-50 mM, 6-h pulse, Figure 1b 
Senescent MPM cells secrete cytokines and pro-mitogenic factors
The coexistence of both senescent and clonogenic cells within the pemetrexed-treated MPM cells suggest that paracrine factors produced by senescent MPM cells could modulate the behavior of the neighboring cell subpopulations, according to a SASP model (Coppe et al., 2010) . Quantitative PCR (Q-PCR) revealed that pemetrexed (and not vehicle)-treated MSTO211H cells showed upregulation of IL6, IL8, VEGF-A and of IFNg, CXCL1 and PlGF1 mRNAs (Figure 1e ), which paired with the increased secretion of the mentioned factors in the conditioned medium (CM) (Figure 1f ). This response was a feature of other pemetrexed-treated MPM cell lines (Supplementary Figure 2A) .
CM derived from senescent MPM cells triggers EMT features in vitro and in vivo
We tested the effect of CM from pemetrexed-treated (p-CM), senescent MSTO211H cells on their untreated counterparts (as compared with CM from vehicletreated cells (v-CM)). We found that p-CM (and not v-CM) treated cells acquired a scattered, elongated fibroblast-like morphology, reminiscent of a mesenchymal phenotype (Figure 2a , left vs right panels). Notably, no or little induction of cell senescence was observed in the p-CM-treated cell populations ( Figure 2b) . Next, we found that p-CM treated cells were strongly vimentinpositive (Figure 2c left vs right panel) and showed an increased migratory capacity (Figure 2d , left and right panels). QRT-PCR revealed high levels of ICAM1 and fibronectin mRNAs (Figure 2e) , and a significant increase of vimentin, MMP-9 and of two EMTeffectors, such as SNAIL and SLUG (Figure 2e ). All of the upregulated genes have been associated with the acquisition of EMT and invasive properties in solid malignancies (Ruco et al., 1996; Scarpa et al., 2002; Sivertsen et al., 2006; Schramm et al., 2010; Casarsa et al., 2011) . p-CM treatment of other MPM cell lines triggered similar changes (Supplementary Figure 2B) . Next, to test whether the p-CM-induced effects contributed to the acquisition of tumorigenic properties in vivo, we performed xenograft transplantation assays (Figure 2f ). Analysis of the clinical signs of the xenografted mice revealed that mice transplanted with p-CM-pretreated MSTO211H and NCI-H2052 cells (1 week before transplantation) showed a higher frequency and reduced latency of tumor development (Supplementary Figures 2C and D) . This significantly affected mice survival (66.6% vs 16.7% residual survival for v-CM and p-CM-treated MSTO211H cells, and 100% vs 33% residual survival for v-CM and p-CM-treated NCI-H2052 cells at day 115, respectively, Po0.05, Figure 2f ). These observations pair with the results of the in vitro clonogenic assays (Figure 1b , lower panel).
p-CM-induced MPM cell subpopulations are enriched for ALDH bright cells In many solid tumors, the expression of high levels of ALDH has been associated to the presence of tumorigenic, invasive and chemoresistant cell subpopulations (Adhikari et al., 2011) . Interestingly, fluorescenceactivated cell sorting (FACS) analysis revealed that the EMT-like, p-CM-(and not v-CM) selected cell subpopulations were highly enriched for ALDH bright cells (Figure 3a) . Notably, treatment with p-CM strongly increased the number of ALDH bright cells in all the analyzed MPM cell lines (Supplementary Figure 3A) . This suggests that soluble factors in the medium of the pemetrexed-treated cells can modulate the number of ALDH bright cells. Indeed, FACS analysis revealed that some of the cytokines identified in the p-CM increased the number of ALDH bright cells, with PlGF1, IL8, VEGF and IFNg being the most effective in this regard (Figure 3b) . We also observed a degree of crosstalk between the identified factors: for example, IL8, VEGF and IFNg treatment increased the levels of PlGF1mRNA (Supplementary Figure 3B) (Figures 3c and d ). This showed that purified ALDH bright cells were highly resistant to pemetrexed treatment ( Figure 3c ) and highly clonogenic (Figure 3d) (Supplementary Figure 4) . Q-PCR analysis of freshly Senescence-driven chemoresistance of MPM C Canino et al purified MPM ALDH bright cells revealed higher mRNA levels of MMP9 and of other two EMT factors, such as SNAIL and SLUG (Figure 3f ), which correlated with the higher invasive ability of ALDH bright cells. We also found very high mRNA levels of ABCG2, Nanog, Oct4, Musashi and Sox2, with Nanog, Sox2 and OCT4 being upregulated 470-folds in ALDH bright cells (Figure 3g ). Expression of the latter genes is associated with a poorly differentiated, tumorigenic cell phenotype in many solid malignancies (refer Discussion). Therefore, p-CM-induced ALDH bright cells show both EMT-like and TIC features. (Figure 4c ). In line with this, we found that treatment of naive ALDH bright from MSTO211H cells with CM from ALDH bright -treated cells increased dose-dependently the number of ALDH bright cells (Figure 4d ), and that rIL6 and rIL8 had similar growth-promoting effects (Figure 4e ). This suggests that the increase in ALDH bright cell number induced by pemetrexed treatment of MPM cells may be mediated by IL6 and IL8 produced in a cellautonomous manner.
ALDH
bright cells exist in vivo and survive pemetrexed treatment To assess whether the observed SASP-induced ALDH bright cell subpopulations exist within primary samples, we derived primary cells by mechanical and enzymatic disaggregation of freshly excised human surgical specimens (meso nos. 1, 2 and 4) or from pleural effusions (meso nos. 3 and 5-9). FACS analysis showed that a variable percentage of ALDH bright cells could be readily identified in 9 out of 9 samples (Supplementary Figure 5 ). We found that 9/9 MPM primary cell cultures survived chronical pemetrexed treatment (2 weeks-10 mM every 72 h) and 8/9 showed a timedependent increase of ALDH bright cells (Figure 5a ), together with a concomitant increase of SA-b-Gal-positive cells (Figure 5b ). Soft-agar CFA assays revealed that chronically selected primary cultures were more clonogenic than those exposed to vehicle alone (Figure 5c , inset).
SASP modulates MPM development in primary MPM xenografts
We then investigated whether the increase of ALDH bright cells in MPM primary cultures correlates with their tumorigenicity in vivo. Quasi-orthotopic transplantation assays with two primary cultures (meso nos. 4 and 5) revealed that NOD/SCID mice transplanted with pemetrexed-selected cells developed peritoneal mesothelioma with higher efficiency (3/6 for meso no. 4 and 6/6 for meso no. 5 and at day 81 post-injection (p.i.), Senescence-driven chemoresistance of MPM C Canino et al respectively, Figure 5d ) as compared with those transplanted with vehicle-treated cells (0/6 for meso no. 4 and 1/6 for meso no. 5 at day 81 p.i., respectively, Figure 5d ). Morphological analysis (H/E (hematoxylin and eosin) and staining for human calretinin) of the formalin-fixed excised lesions confirmed the human nature of the material and the diagnosis of malignant mesothelioma in all cases (Figure 5e) . Notably, FACS analysis of the excised tumors (when available) revealed that the lesions generated by chronically treated MPMs were significantly enriched for ALDH bright cells (13.5 ± 2% vs 35 ± 5% for meso no. 5 vs meso no. 5-pemetrexed tumors, respectively, Figure 5d ). Moreover, we found that mRNA levels of ICAM1, Fibronectin, Vimentin, as well as those of Oct4, Nanog and ABCG2 were higher in the more aggressive tumors (Figure 5f upper and lower panel). We also found that intratumoral mRNA levels and the quantity of secreted IL8, PLGF and VEGF-A into the peritoneal lavage fluid of mice were significantly increased in mice transplanted 
RAS
V12
-induced SASP modulates MPM ALDH bright cell number Expression of oncogenic RAS has been shown to induce a strong SASP in untransformed fibroblasts, and this appears to be restrained by the p53 pathway (Coppe et al., 2008) . Therefore, to widen our observations regarding the pemetrexed-induced SASP in MPM cells, we tested whether expression of oncogenic RAS induces similar changes into HMC cells, and whether alteration of the p53 pathway could enhance the effect of RAS , respectively) and 5 days later we performed RNA interference with either scrambled-or p53-targeting small hairpin RNAs (shRNAs) (Figure 6 ). We found that RAS V12 expression induced the appearance of flat, enlarged SA-b-Galpositive cells in both scrambled-and shP53-transfected cells within 8 days p.i. (Figures 6a and b) . This paired with a strong induction of IL6, IL8, IFNg and CXCL1 mRNAs, which were higher in RAS STAT3 signaling is required for the SASP-induced chemoresistance in vivo and in vitro Some of the cytokines we identified in the p-CM or induced by RAS v12 expression are known to activate STAT3 signaling (such as IL6 and IFNg) or to be STAT3 target genes (such as VEGF, PLGF and IL8). In line with this, we found that p-CM treatment of both HMC and MPM cells induced a significant increase of STAT3 (Y 705 ) phosphorylation in absence of changes in the STAT3 protein levels (Figure 7a ). In addition, p-CM treatment promoted an increased nuclear accumulation of p-STAT3 (Y 705 ) (Figure 7b ). To assess the relevance of STAT3 phosphorylation for the p-CM-induced effects, we generated MPM cell lines stably knocked down for STAT3 (Figure 7c ). We found that STAT3 (Figure 7f) . Finally, we found that induction of some EMT genes by p-CM was strongly reduced as well (Figure 7g ). To investigate whether STAT3 activation has a role in mediating SASP-induced effects in vivo, we performed xenograft assays with either scrambled-or -STAT3 k/d MSTO211H (scrambled and shSTAT3, respectively). We started pemetrexed treatment (i.p injection every 3 days at 100 mg/kg, Figure 7h , arrows) when the engrafted tumors were X0.1 cm 3 in volume (day 1, Figure 7h ). First, we observed that among the vehicle-treated mice, the tumors formed by STAT3 k/ d cells were smaller as compared with the ones formed by control cells (Figure 7h ). In addition, we found that all the engrafted tumors were sensitive to pemetrexed treatment (Figure 7h 
Discussion
The work presented on this paper investigates mesothelioma chemoresistance, a major feature of MPM, which strongly influences the history of the disease. We show here, for the first time, that pemetrexed treatment of mesothelioma cell lines and primary MPM cells readily induces a senescent phenotype with features of SASP (Coppe et al., 2010) (Figure 1 ). SASP consists of premature senescence and secretion of a complex mix of cytokines, chemokines and growth factors (Laberge et al., 2011) . We show that treatment of naive MPM cells with CM derived from pemetrexed-treated MPM cells promotes the emergence of mesenchymal-like, chemoresistant cell subpopulations endowed with high levels of ALDH activity (ALDH bright cells). ALDH bright cells are a minor fraction of unfractionated MPM cell populations. However, purified ALDH bright cells (as compared with ALDH low cells) show prominent tumorigenic properties in vitro, and their number correlates with frequency and latency of mesothelioma development in NOD/SCID mice (Figures 2 and 5 ). In addition, purified ALDH bright cells rapidly generate ALDH low cells and reconstitute the composition of the originating culture, according to a 'progenitor-like' status (Supplementary Figure 4) . ALDH low cells, in turn, produce cytokines that promote expansion of ALDH bright cells (Figures 3b and 4c) . Therefore, both ALDH low and ALDH bright cell subpopulations may closely cooperate in determining the transformed MPM phenotype through cell-autonomous as well as non-autonomous mechanisms (Figure 8, model) . EMT-like cells with high ALDH activity and tumorigenic features have been described in many solid and non-solid tumors (Charafe-Jauffret et al., 2010; Cioce et al., 2010; Kryczek et al., 2011; Ma and Allan, 2011; Marcato et al., 2011; Wang et al., 2011) . In addition, it has been recently shown that the expansion of breast ALDH bright cells is sustained by mesenchymal bone marrow-derived cells. This is mediated by IL-8 . Mesothelial cells acquire mesenchymal features in response to a variety of inflammatory conditions (Park et al., 2003; Aroeira et al., 2007; Kim et al., 2011) . It is tempting to speculate whether mesothelial cells may functionally substitute the bone marrow-derived cells described by Liu et al. (2011) during the inflammation-driven progression of MPM. This is the first time, to our knowledge, that a direct link between SASP and chemoresistance has been addressed. Interestingly, this is significant in regards to the inverse relationship between expression of senescence markers and patient survival observed by Sidi et al. (2011) in chemo-treated primary MPMs. Thus, the presence of senescent MPM cells within growing tumours seems to be required for tumour survival. Our in vivo studies do not demonstrate that ALDH bright cells are responsible for MPM development. However, the pro-tumorigenic behaviour demonstrated by ALDH bright cells in vitro and in vivo calls for future studies to be conducted on a larger cohort of patients. An increase of ALDH bright cells (for example, in the pleural exudate of patients) could be of diagnostic or prognostic value in staging MPM.
We attempted to explain SASP-mediated signaling in pemetrexed-treated cells in more detail. We identified STAT3 activation as a crucial event downstream to SASP-induced cytokine signaling in MPM cells. STAT3 is a possible prerequisite for the modulation of EMT genes by SASP-induced cytokines, and is important to maintain the ALDH bright cell pool (Figure 7) . In fact, shRNA-mediated depletion of STAT3 potentiates the effect of pemetrexed in vivo (Figure 7) . The relevance of STAT3 signaling for MPM cells is reinforced by the observation that most SASP cytokines identified here are either STAT3 activators (IL6 and IFNg) or known Senescence-driven chemoresistance of MPM C Canino et al STAT3 target genes (IL8, PLGF and VEGF) (Takeda and Akira, 2000; Schindler et al., 2007; Oka et al., 2010; Huang et al., 2011a,b) . Notably, some of them are prognostically relevant for MPM in vivo, such as PLGF1 Pompeo et al., 2009) . Additionally, nuclear positivity for pSTAT3 has been described in 60% of malignant mesothelioma cases (Achcar Rde et al., 2007) . Our data suggest that the involvement of p53 pathway in MPM, typically considered as a wtp53-carrying tumor (Metcalf et al., 1992; Mor et al., 1997) , must be further investigated. We show that RNAi-mediated (Figure 6 ). Despite our data being obtained by artificially manipulating the levels of p53 in wtP53-HMC and -MPM cells (Supplementary Figure 6) , evidence that downstream p53 signaling may be altered in MPM is accumulating. It is worthy to note that downregulation of mir-34 b/c (by promoter methylation) in MPM cells has been recently described by Kubo et al. (2011) . Mir-34b/c are direct transcriptional targets of p53 and part of the p53 tumor suppressor network (He et al., 2007; Hermeking, 2007) . In addition, some of the deregulated targets of mir-34 b/c may be involved in SASP signaling, such as cMet (Corney et al., 2007) , which is the HGF ligand. The MET/HGF axis is frequently altered in MPM (Tolnay et al., 1998) . We suggest that the strong tendency of mesothelial cells undergoing EMT upon inflammatory stimuli (such as asbestos exposure) and functional alterations of the p53 pathway (with consequent deregulation of possible SASP effectors) may favor the emergence of SASP-induced chemoresistant cell subpopulations in MPM. We observed that SASP-induced tumorigenic properties (EMT, chemoresistance, acquisition of migratory/invasive properties and progenitorlike features) appear to be mediated by distinct sets of cytokines with partially overlapping functions. This may explain the limited therapeutic efficacy of single cytokine-targeting agents in MPM observed to date (Li et al., 2007; Bais et al., 2010; Suzuki et al., 2010; Yao et al., 2011) . Therefore, we believe that interference with STAT3 signaling (a broad modulator of SASP-induced effects) may be a promising strategy in counteracting MPM chemoresistance.
Materials and methods
Cell lines and culture conditions
The human MPM cell lines MSTO211H, NCI-H28, NCI-H2052 and NCI-H2452 were obtained from the ATCC (Rockville, MD, USA). MPP-89 cells were obtained from the Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy. HMC cells were from Tebu-Bio, Le Perray en Yvelines, France. All the cell lines were cultured as monolayers at 37 1C and 5% CO 2 in DMEM/F12 þ GLUTAMAX (InvitrogenGibco, Carlsbad, CA, USA) supplemented with 10% non-heat inactivated FBS (fetal bovine serum) (Invitrogen-Gibco) and 5 mg/ml insulin (Sigma-Aldrich, St Louis, MO, USA). Before treatment with CM or recombinant cytokines, cells were shortly (6 h) cultured in starvation medium DMEM/ F12 þ GLUTAMAX supplemented with 1% BSA-FAF (fatty acid-free bovine serum albumin) and 5 mg/ml insulin (Sigma-Aldrich).
Primary MPM cultures
Primary MPM cultures (meso nos 1, 2 and 4) were generated as follows: briefly, solid tissues were manually minced and subjected to collagenase/ialuronidase digestion (300U/100U, respectively) for 2 h in digestion medium (DMEM/ F12 þ GLUTAMAX supplemented with 1% BSA-FAF and 5 mg/ml insulin). Digested material was then filtered through a nylon mesh (70 mm), collected by gentle centrifugation and resuspended in fresh medium DMEM/F12 þ GLUTAMAX (1:1, Invitrogen, Carlsbad, CA, USA) supplemented with 5% non-heat inactivated FBS, insulin 10 mg/ml and ciprofloxacin (4 mg/ml). Pleural effusions (meso nos 3, 5 and 9) were centrifuged for 10 min at 1000 r.p.m. before being treated as primary MPMs.
ALDH activity assay and cell sorting ALDH activity was detected in situ by using a fluorescence microscope or by FACS analysis (Guava easyCyte, Millipore, Billerica, MA, USA). ALDEFLUOR kit (Stem Cell Technologies, Vancouver, Canada) was used in both cases, according to the manufacturer's instructions. Sorting of MPM cell subpopulations was performed by using a MoFlo FACS instrument (DAKOCytomation, Carpinteria, CA, USA) equipped with a refrigerated chamber. ALDH-positive cells were defined as the cells that displayed greater fluorescence compared with a control staining reaction containing the ALDH inhibitor, DEAB (diethylaminobenzaldehyde).
Cell viability assay
Cell viability of treated cells was assessed by ATPlite assay (Perkin Elmer, Boston, MA, USA) according to manufacturer's instructions. Cytokine quantification Levels of secreted IL6, IL8, IFNg and VEGF from CM or peritoneal washing fluid of mice were quantitated by Human Singleplex Bead Kit (Invitrogen). Quantikine Immunoassay (R&D) was used to quantify CXCL1 and PlGF1 levels, respectively.
Reagents and cytokines
BrdU incorporation assay
Detection of BrdU incorporation was performed by ELISA (BrdU Cell Proliferation Assay Kit, Cell Signaling Technology, Danvers, MA, USA) according to the manufacturer's instructions.
Wound healing assay Cells grown to 95% confluence were seeded in 6-well tissue culture plates and wounded with a sterile 10-ml pipette tip to remove cells. Digital micrographs were taken after scratching and at the indicated times.
Invasion assay
Matrigel invasion assays were performed as follows: Briefly, 20 mg per well of Matrigel (BD Biosciences) were applied to 24-well transwell plates with 8 m pore size (BD Biosciences) and allowed to solidify overnight. 30 000 cells resuspended in fresh medium were seeded into each well. The plates were incubated at 37 1C for 72 h, and then cells at the bottom were fixed and stained. Transmigrated cells were normalized for initial number of seeded live cells or subjected to in situ ALDH assay, as indicated before.
Clonogenic assay MPM cells were seeded at 100 (ALDH bright )-5000 (bulk) cells per 6-well dish. Formed colonies were stained with crystal violet 10-15 days later. When indicated, cells were resuspended in 0.3% methylcellulose before plating.
Q-PCR
Total RNA was extracted using the Trizol Reagent (Gibco). The first-strand cDNA was synthesized according to manufacturer's instructions (M-MLV RT kit, Invitrogen). Gene expression was measured by real-time PCR using the SybrGreen assay (Cell Signaling Technology) on a 7900HT instrument (Applied Biosystems). Q-PCR primers are reported in Supplementary Table 1 .
Xenograft transplantation
Suspensions of 1 Â 10 6 MSTO211H cells were injected i.p. (Figure 1 ) or s.c. (Figure 7 ) in PBS1X/Matrigel (BD Biosciences) into 5-weeks-old male CD1 mice (Charles River, Milan). Body weight and clinical signs of the mice were determined every 3 days, and in case of i.p. transplantation, mesothelioma development was suggested by the presence of 42 g per week variation of body weight, worsening of clinical symptoms and appearance of ascitic fluid. For s.c. transplantation, tumor volume was calculated using the formula: V ¼ p/6 Â length Â width (by manual caliper). Mice were treated i.p. with pemetrexed (100 mg/kg per 3 days, n ¼ 4) when the tumor volume was X0.1 cm 3 . All tumorigenicity assays were carried out according to the guidelines set by the Internal Ethical Committee.
MPM transplantation in NOD/SCID mice Suspensions of 0.5 Â 10 6 human primary MPM cultures were injected i.p. in PBS1X/Matrigel (BD Biosciences) into 5-weeksold male NOD/SCID mice (Charles River Laboratories, Calco, LC, Italy). Body weight and clinical signs of the mice were determined as described before. Diagnosis of malignant mesothelioma was confirmed by expert pathologists (H/E and anti-human calretinin staining (Ventana Medical Systems, Oro Valley, AZ, USA) of nine representative sections of each excised lesion).
Western blot
For Western blotting, the following antibodies were used: antipSTAT3 (Tyr-705) (#sc-8059), anti-STAT3 (#sc-7179), antiTubulin (#sc-23948) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-p53 (DO-1, Calbiochem, San Diego, CA, USA).
Immunofluorescence microscopy Briefly, cells were fixed/permeabilized in paraformaldehyde/ methanol, aspecific binding blocked in PBS containing 1% bovine serum albumin, and labeled with anti-Vimentin antibody (VIM-13.2 Sigma, 1:100 dilution), p-STAT3 (Tyr-705) (#sc-8059) or p53 (pantropic DO-1, Calbiochem). The secondary antibody was an Alexa 488-conjugated goat antimouse IgG (Calbiochem). Nuclei were visualized by 4 0 ,6-diamidino-2-phenylindole (DAPI) staining.
Retroviral transduction of HMC and MPM cells
The pBabe, pBabe-Ras V12 , pRETRO SUPER p53, pRETRO, pSIH1-puro-STAT3 shRNA and pSIH1-puro-scrambledshRNA (plasmids 26596 and 26597, Addgene, Cambridge, MA, USA) constructs were transfected into the 293T packaging cells (Invitrogen) by Ca-PO 4 precipitation method. Virus-containing supernatants were used to infect MPM or HMC cells (three cycles of infection). Cells were selected by puromycin (1 mg/ml every 48 h for 1 week). Senescence-driven chemoresistance of MPM C Canino et al
Statistical analysis
Student's t-test was used to assess significance of the in vitro data, whereas the significance of mice survival data was determined by using Kaplan-Meier analysis and Log Rank test for statistical significance. P values of p0.05 were considered statistically significant. When indicated, asterisks indicate no statistically significant differences between the labeled samples.
Abbreviations
EMT, epithelial-to-mesenchymal-transition; MPE, mesothelial peritoneal exudate; SASP, senescence-associated-secretory-phenotype; TICs, tumor-initiating-cells.
